For the first time, a government-funded UK trial will investigate psilocybin-assisted psychotherapy for targetting relapses associated with opioid addiction, aiming to bring an innovative new therapy...
The UK’s first trade association for psychedelics – Psychedelic Industry UK (PsyIndyUK) – has launched today, 18 September, to represent the country’s growing psychedelic medicine sector.
Awakn Life Sciences has entered into a new collaboration with Graft Polymer to advance its New Chemical Entity (NCE) programme, developing novel molecules for innovative addiction...
An emerging body of evidence is showing psychedelics as promising treatments for mental health conditions, and psychiatry needs to be prepared for their arrival, say researchers.
The UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for post traumatic stress disorder (PTSD).
The UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for anxiety disorders.
Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...
In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
Launching in 2008 as a drug literature review blog by Rob Dickins, Psychedelic Press has brought readers a host of unique insights into psychedelic thought and...
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
